| Recipient age / yrs (median (IQR) |
49 (37–61) |
| Male recipients, n (%) |
64 (59) |
| Recipient ethnicity, n |
|
| White |
75 |
| Indo-Asian |
23 |
| African-Caribbean |
7 |
| Other |
3 |
| Cause of renal failure, n (%) |
|
| Glomerular |
22 (20) |
| Hereditary/cystic |
25 (23) |
| Diabetes |
7 (6) |
| Vascular |
24 (22) |
| Interstitial |
7 (6) |
| Other |
23 (21) |
| Donor age (yr) |
48.9 |
| Transplant source, n (%) |
|
| Deceased donor |
|
| DBD |
49 (45.4) |
| DCD |
8 (7.4) |
| Live donor |
51 (47.2) |
| Donor-recipient HLA mismatch |
|
| HLA-A |
1.1 |
| HLA-B |
1.0 |
| HLA-DR |
0.7 |
| Donor-recipient CMV serostatus |
|
| D—R— |
30 |
| D—R+ |
25 |
| D+R+ |
32 |
| D+R— |
21 |
| Day recruited post-transplantation (days) (interquartile range) |
84 (79–91) |
| Immunosuppression on recruitment |
|
| (Basiliximab induction) |
(108) |
| Tacrolimus |
106 |
| MMF |
98 |
| Corticosteroid |
108 |
| Biopsy proven acute rejection |
9 |
| Patient survival at 9 months post-recruitment (1 year post transplantation), n (%) |
108 (100) |
| eGFR (ml/min) (SD) 12 months post transplantation in surviving transplants |
52 (30) |
| Graft survival at 9 months post recruitment (1 year post-transplant) n (%) |
107 (99) |
| CMV disease at 12 months (5 D+R-, 1 D+R+, 1 D-R+) n |
7 |
| CMV QNAT > 5000 copies /mL at any time-point, n |
12 |
